GLUE
Q4 2026 EPS Estimate
$-0.36
Nov 5, 2026 · Reports before open
Revenue Estimate
$19M

Analyst Sentiment

Wall St. Consensus
Buy
8 analysts·Limited coverage
72
Score
7 Buy (88%)1 Hold (13%)0 Sell (-1%)
Rating Breakdown
Strong Buy
00%
Buy
788%
Hold
113%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$25.00
+73.6%
Consensus
$27.00
+87.4%
Bull
$28.00
+94.4%
12-Month Target Range8 analysts
$25.00$27.00$28.00
Current $14.40Consensus
Current Price
$14.40
Upside to Consensus
$12.60

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+6.33%
EPS
FY2028
Rev+114.28%
EPS
FY2029
Rev+0.92%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$54M$57M$122M$123M$143M
Low$15M$15M$32M$32M$37M
High$120M$137M$336M$340M$394M
EBITDA Avg$21M$22M$47M$48M$55M
Low$6M$6M$12M$12M$14M
High$46M$53M$130M$131M$152M
EBIT Avg$19M$20M$43M$43M$50M
Low$5M$5M$11M$11M$13M
High$42M$48M$118M$119M$138M
Net Income Avg$-92M$-200M$-172M$-137M$-122M
Low$-150M$-202M$-197M$-448M$-399M
High$-33M$22M$60M$-5M$-5M
EPS Avg$-1.63$-1.90$-1.67$-2.09$-1.86
Low$-2.29$-3.09$-3.00$-6.84$-6.08
High$-0.50$0.34$0.91$-0.08$-0.07
Analysts (Rev / EPS)5 / 55 / 56 / 64 / 33 / 2
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg$19M$22M$4M$4M$5M$5M
Low$4M$3M$587,849$587,849$758,516$758,516
High$44M$55M$9M$9M$12M$12M
EBITDA Avg$7M$8M$1M$1M$2M$2M
Low$1M$1M$226,484$226,484$292,238$292,238
High$17M$21M$4M$4M$5M$5M
EBIT Avg$7M$8M$1M$1M$2M$2M
Low$1M$955,174$205,915$205,915$265,697$265,697
High$15M$19M$3M$3M$4M$4M
Net Income Avg$-31M$-33M$-49M$-52M$-52M$-54M
Low$-57M$-91M$-142M$-151M$-149M$-155M
High$12M$69M$5M$5M$5M$6M
EPS Avg$-0.36$-0.38$-0.58$-0.61$-0.61$-0.63
Low$-0.67$-1.07$-1.67$-1.77$-1.75$-1.82
High$0.14$0.81$0.06$0.06$0.06$0.06
Analysts (Rev / EPS)5 / 55 / 54 / 34 / 34 / 34 / 3

Earnings Surprises

Recent Analyst Actions

Aug 7, 2026Guggenheim
Monte Rosa Therapeutics price target lowered to $28 from $35 at Guggenheim
Target:$28.00
+78.2%from $15.71
Aug 3, 2026Wedbush
Monte Rosa Therapeutics price target lowered to $27 from $37 at Wedbush
Target:$27.00
+67.0%from $16.16
Jul 31, 2026Jefferies
Monte Rosa Therapeutics price target lowered at Jefferies after Novo trial miss
Target:$25.00
+51.3%from $16.52
Jul 27, 2026Jefferies
Monte Rosa Therapeutics (GLUE) PT Raised to $40 at JefferiesMember Login
Target:$40.00
+75.6%from $22.78
Jun 30, 2026Guggenheim
Monte Rosa Therapeutics (GLUE) PT Raised to $35 at GuggenheimMember Login
Target:$35.00
+46.4%from $23.90
Jan 14, 2026Piper Sandler
Monte Rosa Therapeutics price target raised to $37 from $27.50 at Piper Sandler
Target:$37.00
+54.2%from $23.99
Jan 7, 2026Jefferies
Monte Rosa Therapeutics price target raised to $31 from $22 at Jefferies
Target:$31.00
+33.1%from $23.29
Jan 7, 2026Wedbush
Monte Rosa Therapeutics price target raised to $37 from $26 at Wedbush
Target:$37.00
+52.2%from $24.31
Dec 17, 2025Jefferies
Monte Rosa Therapeutics (GLUE) PT Raised to $22 at Jefferies
Target:$22.00
+17.9%from $18.66
Dec 16, 2025Wells Fargo
Monte Rosa Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
Target:$22.00
+33.7%from $16.45
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.